La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

InnoCan Pharma Bilan de santé

Santé financière contrôle des critères 6/6

InnoCan Pharma possède un total de capitaux propres de $6.0M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $8.7M et de $2.7M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$5.19m
Fonds propres	US$6.04m
Total du passif	US$2.68m
Total des actifs	US$8.72m

Mises à jour récentes de la santé financière

Recent updates

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Aug 09

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

May 04

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Dec 06

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

Aug 15

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

Apr 19

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Jul 20

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Apr 05

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de INNO ( $8.6M ) dépassent ses passifs à court terme ( $2.7M ).

Passif à long terme: Les actifs à court terme de INNO ( $8.6M ) dépassent ses passifs à long terme ( $4.0K ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: INNO est sans dette.

Réduire la dette: INNO n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 32.9%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: INNO dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: INNO dispose d'une marge de trésorerie suffisante pour 1.6 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 7.4 % chaque année.

InnoCan Pharma Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Recent updates

InnoCan Pharma Corporation announced that it expects to receive CAD 0.88 million in funding

Second quarter 2024 earnings released: EPS: US$0.001 (vs US$0.002 loss in 2Q 2023)

We're Hopeful That InnoCan Pharma (CSE:INNO) Will Use Its Cash Wisely

Innocan Pharma Corporation Submits Investigational New Animal Drug Application to FDA's Veterinary Center

First quarter 2024 earnings released: US$0.007 loss per share (vs US$0.005 loss in 1Q 2023)

Innocan Pharma Corporation Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

It's Probably Less Likely That InnoCan Pharma Corporation's (CSE:INNO) CEO Will See A Huge Pay Rise This Year

Full year 2023 earnings released: US$0.018 loss per share (vs US$0.015 loss in FY 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.98821 million in funding

InnoCan Pharma Corporation, Annual General Meeting, May 09, 2024

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

Third quarter 2023 earnings released: US$0.008 loss per share (vs US$0.001 loss in 3Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.627682 million in funding

InnoCan Pharma Corporation announced that it expects to receive CAD 3 million in funding

InnoCan Pharma Corporation Announces Appointment of Dr. Joseph V. Pergolizzi to its Scientific Advisory Board

Second quarter 2023 earnings released: US$0.002 loss per share (vs US$0.007 loss in 2Q 2022)

InnoCan Pharma Corporation announced that it has received CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it expects to receive CAD 1.934239 million in funding

New minor risk - Shareholder dilution

InnoCan Pharma Corporation announced that it has received CAD 3.9606 million in funding

Innocan Pharma Corporation Submits New Patent Applications for Advanced Pain Relief Technology

First quarter 2023 earnings released: US$0.005 loss per share (vs US$0.003 loss in 1Q 2022)

InnoCan Pharma Corporation Announces Successful Treatment of Billy with Liposomal-CBD Injection in Pre-Clinical Trial

Full year 2022 earnings released: US$0.015 loss per share (vs US$0.045 loss in FY 2021)

InnoCan Pharma Corporation announced that it has received CAD 0.4955 million in funding

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Third quarter 2022 earnings released: US$0.001 loss per share (vs US$0.016 loss in 3Q 2021)

Innocan Pharma Corporation Announces the Addition of Givi Topchishvili, to Advisory Committee, as A Business Strategy Adviser

Less than half of directors are independent

Innocan Pharma Corporation Announces Additional Positive Results in New Preclinical Trial Involving A Dog with Refractory Epilepsy

Second quarter 2022 earnings released

InnoCan Pharma Corporation Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

We Think InnoCan Pharma (CSE:INNO) Can Afford To Drive Business Growth

InnoCan Pharma Corporation Announces Results Approaches 100% Bioavailability Following Subcutaneous Injection of Its CBD Proprietary LPT Delivery System in A Clinical Study Conducted on Dogs Suffering from Pain

InnoCan Pharma Corporation Files PCT Patent Application for Novel Composition for Preventing and Treating Hair Loss

Innocan Pharma Corporation Files PCT Patent Application for Diabetic Symptoms

InnoCan Pharma Corporation Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures on Dog Using LPT

Innocan Pharma Corporation Reports Successful Preclinical Dog-Trial Results Regarding Pain Management

Innocan Pharma Corporation Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment

First quarter 2022 earnings released

Less than half of directors are independent

Companies Like InnoCan Pharma (CSE:INNO) Are In A Position To Invest In Growth

InnoCan Pharma Corporation Reports Successful FDA Required Characterization of Highly CBD Loaded Liposome Platform

Is InnoCan Pharma (CSE:INNO) In A Good Position To Deliver On Growth Plans?

Innocan Pharma Corporation Cbd Integrated Anti-Aging Sleeping Mask Demonstrates A Reduction of the Appearance of Wrinkles by Up to 28.8% in 4 Weeks of Clinical Study

Innocan Pharma Corporation Completes a Cosmetic Clinical Study of SHIR® CBD Eye Serum on 22 Volunteers

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Vaginal Moisturizer and Lubricant Treatment

Innocan Pharma's Liposome Platform Technology Demonstrates a 7-Week Prolonged Release of CBD into Bloodstream in Recent Animal Study

Innocan Pharma's CBD Loaded Liposome Platform Technology Receives Positive Results from Recent Animal Study

We Think InnoCan Pharma (CSE:INNO) Needs To Drive Business Growth Carefully

Innocan Pharma Announces Patent Application for Novel Cannabis-Based Anti-Itch Treatment

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in the US and the Launching of Its US Commercial Online Platform

Innocan Pharma Announces Successful Production of CBD Loaded Liposomes Under Aseptic Conditions

New 90-day high: CA$0.41

InnoCan Pharma Corporation Announces Successful Completion of a Large-Scale Production of Exosomes

InnoCan Pharma Corporation announced that it has received CAD 2.367804 million in funding

New 90-day high: CA$0.31

InnoCan Pharma Corporation Announces the Completion of Its First Full-Scale Manufacturing Run in Europe and the Commencement of its Full-Scale Manufacturing Run in the USA

Innocan Pharma Corporation Announces the Launch of Two Therapeutic Studies on Small and Large Animals Examining the Therapeutic Efficacy of CBD Loaded Liposome Platform Technology in Relevant Diseases

New 90-day high: CA$0.30

Innocan Pharma's Clinical Study in the US Indicates That More Than 90% of Participants Experienced Pain Reduction After Using Innocan's Relief & Go OTC Pain Relief Spray

Innocan Pharma's Cosmetic Clinical Study Indicates a 90% Wrinkle Reduction After Using Its SHIR(TM) Premium CBD Facial Serum

Innocan Pharma Corporation Provides Clinical Update of its Unique CBD-Loaded Liposome Platform Technology for Injectable CBD

New 90-day high: CA$0.24

InnoCan Pharma Corporation Completes Successful Cosmetic Clinical Studies

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan